ZRANB2 and SYF2 mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. ZRANB2 and SYF2 mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin

We explored the regulation of alternative splicing in a cell model of breast cancer resistance to doxorubicin, and the impact of the depletion of two splicing factors (ZRANB2 and SYF2) in this context. Overall design: We analyzed by RNA-seq, alternative splicing regulation between doxorubicin-resistant and sensitive cells, and between resistant cells with ot without depletion of either ZRANB2 or SYF2 (2 independent siRNAs for each, all conditions in triplicate).